Table 1 Baseline demographics of patients receiving at least one dose of infliximab
From: 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
Characteristic | Value |
|---|---|
Age (years) (n = 575) | Â |
   Mean ± SD | 57 ± 13 |
   Median | 58 |
   Range | 19 -99 |
Sex | Â |
   Female, N (%) | 419 (72.9%) |
   Male, N (%) | 156 (27.1%) |
Age at diagnosis (years) (n = 564) | Â |
   Mean ± SD | 46.2 ± 13.6 |
   Median | 47 |
   Range | 5-81 |
Duration of disease (years) (n = 564) | Â |
   Mean ± SD | 10.3 ± 9.4 |
   Median | 8 |
   Range | 0-53 |
HAQ index at screening (n = 573) | Â |
   Mean ± SD | 56.1 ± 15.4 |
   Median | 55 |
   Range | 2-98 |
Swollen joint count at screening (n = 568) | Â |
   Mean ± SD | 16.3 ± 7.5 |
   Median | 14 |
   Range | 0-49 |
MTX doses in mg/week (n = 425) | Â |
   Mean ± SD | 14.5 ± 3.0 |
   Median | 15 |
   Range | 5-25 |
MTX use | Â |
   Yes, N (%) | 537 (93.4%) |
   No, N (%) | 14 (2.4%) |
   Unknown, N (%) | 24 (4.2%) |
NSAID use | Â |
   Yes, N (%) | 414 (72%) |
   No, N (%) | 46 (8%) |
   Unknown, N (%) | 115 (20%) |
Corticosteroid use | Â |
   Yes, N (%) | 341 (59.3%) |
   No, N (%) | 84 (14.6%) |
   Unknown, N (%) | 150 (26.1%) |